Causes, Risk Factors, and Prevention of Waldenstrom Macroglobulinemia
The cause of most Waldenstrom macroglobulinemia (WM) is not completely understood.
Researchers have found a few risk factors that make a person more likely to develop WM. But having a risk factor doesn’t mean you will get the disease. Most people with these risk factors don’t develop WM.
What causes Waldenstrom macroglobulinemia?
Researchers have made great progress in understanding how certain gene mutations (changes) can cause normal cells to become cancerous. For example, some genes contain instructions for controlling when our cells grow and divide.
Mutations in these genes can lead to cancer growth.
We still don’t know exactly what causes Waldenstrom macroglobulinemia (WM), but researchers are beginning to understand how certain gene changes may play a role.
Gene changes found in WM cells
Certain gene changes in normal B cells can alter the way the gene works. When this happens, it can promote cancer growth and lead to a person developing WM.
Scientists don’t yet know the exact cause of gene changes that lead to WM, but they do know that certain gene changes are seen more commonly in WM cells. When doctors know what gene changes are present in WM, they can use this information to help figure out the best treatment and predict how your cancer will respond.
In the case of WM, 4 main gene changes have been seen.
MYD88 gene mutations create an oncogene. These gene changes are seen in >95% of people with WM.
This gene normally helps immune system cells signal each other and helps keep them alive. The DNA change in this gene might make it stay turned on all the time, which could help the WM cells survive longer than they should.
CXCR4 gene mutations create an oncogene, allowing the cancer cells to grow and spread. This gene change is seen in about 1 in 3 people with WM. It is seen in other types of cancer as well.
ARID1A is a tumor suppressor gene. When changes happen to this gene, cells can grow unchecked. This gene change is seen in about 1 in 5 cases of WM.
CD79B gene mutations create an oncogene, promoting cell survival and growth. This gene change is seen in about 1 in 10 cases of WM.
Are these gene changes inherited or acquired?
The changes found in WM cells are usually acquired, meaning they happen after you are born. They are not usually inherited (passed on from a parent).
Some of these acquired changes may have outside causes, but often they happen for no apparent reason. They seem to happen more often as we age, which might help explain why WM usually occurs in older people.
Risk factors for Waldenstrom macroglobulinemia
A risk factor is anything that affects your chance of getting a disease such as cancer. Different cancers have different risk factors. Some risk factors, like smoking, can be changed. Others, like your age or family history, cannot be changed.
Although Waldenstrom macroglobulinemia (WM) is rare, it is most common in:
- Men
- White people
- People over the age of 50
Researchers have found a few other risk factors that make a person more likely to develop WM.
Genetic risk factors
Most WM is caused by acquired gene changes after birth, but some people with a family history of WM may be at an increased risk.
About 1 in 5 people with WM have a close relative with WM or with a related B-cell disease, such as monoclonal gammopathy of undetermined significance (MGUS), or certain types of lymphoma or leukemia.
Environmental risk factors
Studies of environmental exposures suggest that exposure to farming, pesticides, and wood dust may increase the risk of developing WM. More studies are needed to understand if exposure to chemicals or other things in the environment plays a role in WM.
Other risk factors
Monoclonal gammopathy of undetermined significance (MGUS)
Monoclonal gammopathy of undetermined significance (MGUS) is a condition related to multiple myeloma and WM. In MGUS, abnormal plasma cells make many copies of the same IgM antibody (called a monoclonal protein). These plasma cells make up less than 10% of the bone marrow and they do not form an actual tumor or mass.
MGUS itself does not cause health problems, but each year about 1-2% of people with MGUS go on to develop a related cancer like WM, multiple myeloma, lymphoma, or another serious health problem like amyloidosis.
Chronic hepatitis C infection
Some studies have found that people with chronic hepatitis C infection might be more likely to develop WM than people without the virus. But not all studies have found this link.
Certain autoimmune diseases
Some research has suggested that people with certain types of autoimmune disease, such as autoimmune anemias and Sjögren (Sjogren) syndrome, might be at higher risk for WM.
Can Waldenstrom macroglobulinemia be prevented?
Most of the risk factors for Waldenstrom macroglobulinemia (such as older age or MGUS) cannot be changed or controlled, so there is no way to prevent cancers related to these risk factors.
Some research suggests that people with hepatitis C might be more likely to develop WM. There is currently no vaccine to prevent hepatitis C, but avoiding activities like injection drug use or unprotected sex with many partners can reduce the risk of getting the virus.
Researchers don’t know if treating conditions associated with WM, like hepatitis C or autoimmune diseases, changes the risk for developing WM.
- Written by
- References
Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).
Atienza J, Bockorny B, Dadla A, Codreanu I, Dasanu CA. Inflammatory and immune-related conditions associated with Waldenström macroglobulinemia: a single center experience. Leuk Lymphoma. 2015;56(4):1179-1180.
Garcia-Sanz R, Varettoni M, Jiménez C, et al. Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia. Semin Hematol. 2023;60(2):90-96.
Gertz MA. Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management. Am J Hematol. 2025;100(6):1061-1073.
Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297(18):2010-2017.
Krishnan C, Cupp JS, Arber DA, Faix JD. Lymphoplasmacytic lymphoma arising in the setting of hepatitis C and mixed cryoglobulinemia. J Clin Oncol. 2007;25(27):4312-4314.
Kristinsson SY, Koshiol J, Björkholm M, et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst. 2010;102(8):557-567.
Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-569.
Rajkumar SV, Dispenzieri A. Chapter 101: Multiple myeloma and related disorders. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa. Elsevier: 2019.
Royer RH, Koshiol J, Giambarresi TR, Vasquez LG, Pfeiffer RM, McMaster ML. Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation. Blood. 2010;115(22):4464-4471.
Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006;17(3):488-494.
Treon SP, Xu L, Guerrera ML, et al. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020;38(11):1198-1208.
Last Revised: November 17, 2025
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.


